Charalambos (Babis) Andreadis, MD, MSCE
Articles
Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL
January 18th 2019Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).
Dr. Andreadis on Response to CAR T-Cell Therapy
October 16th 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.
Dr. Andreadis on Developments to CAR T-Cell Therapy
January 23rd 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses developments being made to chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.
Dr. Andreadis on the Current State of CAR T-Cell Therapy in Lymphoma
January 22nd 2018Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses chimeric antigen receptor (CAR) T-cell therapy in lymphoma.
Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL
December 29th 2017Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).
